» Articles » PMID: 36582511

Case Report: Exploring Under the Tip of the Iceberg: A Case Series of "self-limiting" Multisystem Inflammatory Syndrome in Children

Overview
Journal Front Pediatr
Specialty Pediatrics
Date 2022 Dec 30
PMID 36582511
Authors
Affiliations
Soon will be listed here.
Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a serious condition triggered by SARS-COV-2 infection, characterized by persistent fever, multiorgan dysfunction, and increased inflammatory markers. It requires hospitalization and prompt treatment, with nearly 60% of the cases needing intensive care and 2% fatality rate. A wide spectrum of clinical characteristics and therapeutic approaches has been reported in MIS-C. We describe a series of four patients with MIS-C, defined according to the current case definitions, with a self-limiting course and no need for immunomodulatory treatment ("self-limiting MIS-C"). Few data about self-limiting MIS-C are available to date and no information on medium- and long-term outcome of this subset of patients has been reported. Although limited in size, our experience provides new insights into the MIS-C syndrome, highlighting an underestimated aspect of the disease that may have significant therapeutic implications.

References
1.
McArdle A, Vito O, Patel H, Seaby E, Shah P, Wilson C . Treatment of Multisystem Inflammatory Syndrome in Children. N Engl J Med. 2021; 385(1):11-22. PMC: 8220965. DOI: 10.1056/NEJMoa2102968. View

2.
Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P . Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020; 395(10237):1607-1608. PMC: 7204765. DOI: 10.1016/S0140-6736(20)31094-1. View

3.
Henderson L, Canna S, Friedman K, Gorelik M, Lapidus S, Bassiri H . American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol. 2022; 74(4):e1-e20. PMC: 9011620. DOI: 10.1002/art.42062. View

4.
Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrot M . Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. 2021; 325(9):855-864. PMC: 7851757. DOI: 10.1001/jama.2021.0694. View

5.
Abrams J, Oster M, Godfred-Cato S, Bryant B, Datta S, Campbell A . Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health. 2021; 5(5):323-331. PMC: 7943393. DOI: 10.1016/S2352-4642(21)00050-X. View